Most big drugmakers abandoned the flu vaccine market, which is far less profitable than that of branded drugs.
Without those kinds of incentives, the vaccine market is still likely to look decidedly iffy to big drug makers.
There's a real likelihood that we will see some fundamental changes in the vaccine market and in vaccine oversight.
National Childhood Vaccine Injury Act of 1986 (the Vaccine Act), allowing state-court judgments against a vaccine manufacturer based on an alleged design defect would wholly undermine the preservation of a robust childhood vaccine market.
FORBES: High Court Upholds Federal Preemption of Design Defect Claims Against Vaccine Makers
In diseases for which there is no private vaccine market, such as pandemic influenza, or for which cases are concentrated in poor countries, such as malaria and tuberculosis, governments and public-private partnerships have stepped in to subsidize development.
The U.S. Food and Drug Administration might not be willing to put a vaccine on the market based on such limited data.
The FDA does have emergency powers to put a drug or vaccine on the market soon, and Adams said that was a distant possibility if something went awry in the federal supply line for the H1N1 vaccine.
CNN: King: H1N1 worries increase awareness on college campuses
By providing a comprehensive, no-fault compensation regime to address vaccine-relate injuries, Congress sought to protect vaccine manufacturers from the same kind of burdensome litigation that previously drove so many vaccine manufacturers from the market.
FORBES: High Court Upholds Federal Preemption of Design Defect Claims Against Vaccine Makers
All these approvals will open the bigger market for the vaccine and will drive the growth.
This, advocates hope, will give a second-generation vaccine time to steal the market from its forerunners.
If all goes well, the vaccine could be on the market in three years' time.
And colleagues at the school also predicted it would be 10 years before a vaccine came on to the market.
The U.S. arm of U.K. pharmaceutical firm SmithKline Beecham agreed in principle with a Cuban biotech institute to develop and market a meningitis vaccine created by the Cubans.
The U.S. arm of British pharmaceutical firm SmithKline Beecham agreed in principle with a Cuban biotech institute to develop and market a meningitis vaccine created by the Cubans.
In a best-case scenario, the earliest Serum's vaccine would be available in the market is April, said Jadhav.
No therapeutic cancer vaccine had ever made it to the market here, despite numerous attempts.
These include adult diseases, such as genital herpes, which give vaccine firms access to a lucrative private market.
Unless another vaccine firm appears from out of the woodwork, in three years there will be four suppliers of vaccine to the U.S. market, yet all of them will be headquartered outside the country.
In 2002 the Institute of Medicine (which is not part of the NIH, but is the health arm of the National Academy of Sciences) called for the creation of a National Vaccine Authority that would have sweeping responsibilities, including market research, the establishment of priorities, control of intellectual-property rights, the conduct of in-house research and development and the financing of clinical trials of candidate vaccines.
The vaccine, Gardasil, is the most promising product brought to market by drugmaker Merck in years.
The vaccine, Gardasil, is the most promising product brought to market by drugmaker Merck (nyse: MRK - news - people ) in years.
Last year, the U.S. flu shot market was so unappealing that only two players were producing injectable vaccine--leading to a serious shortage when one of them, Chiron, had to shut down its plant.
Here are a few posts that you may have missed about the sales potential for the first cancer vaccine, why pharmaceutical giants are failing at their attempts to develop cancer drugs, and the race to market new pills to fight the hepatitis C virus.
应用推荐